Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to document clinical utility and distribution of indications for short term pancreatic stenting, and stent type preference by indication at tertiary referral centers with expertise in pancreatic endotherapy.
The study is designed as an all-comer, prospective, multi-center, consecutive cohort series, open-label study.
Detailed objective: To confirm the clinical utility of Advanix™ Pancreatic Stents when used per standard of practice to facilitate pancreatic duct drainage in the following clinical presentations:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A: PEP Risk | In subjects deemed at high risk for acute pancreatitis post-endoscopic retrograde cholangiopancreatography (ERCP) |
| |
| Group B: Impaired Pancreatic Duct Drainage | In subjects with a pancreatic duct stricture and/or pancreatic duct stones and/or pancreatic duct sludge or debris, possibly, but not exclusively before or after ESWL or before pancreatic surgery |
| |
| Group C: Pancreatic Duct Leak | In subjects with a pancreatic duct leak |
| |
| Group D: Post Pancreatic Surgery | In subjects at risk of pancreatic duct leak or strictures after resection of a pancreatic lesion close to the main pancreatic duct or at the level of the pancreatico-jejunostomy after pancreatico-duodenectomy |
| |
| Group E: Other | In subjects with other indications |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers | Device | Used to drain pancreatic ducts |
|
| Measure | Description | Time Frame |
|---|---|---|
| Clinical Success: Group A (PEP Risk) | Absence of acute pancreatitis from stent placement through 48 hours post stent placement | Stent placement through 48 hours post stent placement |
| Clinical Success: Group B (Impaired Pancreatic Duct Drainage) | Absence of acute pancreatitis from stent placement through stent removal and, where applicable, improvement of pain at stent removal compared to baseline | Stent placement through stent removal |
| Clinical Success: Group C (Pancreatic Duct Leak): | Resolution of pancreatic duct leak at stent removal | Stent Removal |
| Clinical Success: Group D (Post Pancreatic Surgery) | Absence of pancreatic duct leak and stricture at stent removal | Stent Removal |
| Clinical Sucess: Group E (Other) | Resolution of the indication for stent placement at stent removal | Stent Removal |
| Measure | Description | Time Frame |
|---|---|---|
| Serious Adverse Events and all occurrences of acute pancreatitis | Occurrence and severity of serious adverse events related to the stent and/or the stent placement and/or stent removal procedures as applicable and all occurrences of acute pancreatitis. | Through end of study |
| Technical Success |
Not provided
Inclusion Criteria:
Subjects age 18 or older.
Subjects who require pancreatic drainage and are amenable to endoscopic techniques.
Subjects willing and able to comply with the study procedures and follow up schedule and willing to provide written informed consent to participate in the study.
Subjects satisfying at least one of the following clinical presentations:
Exclusion Criteria:
Not provided
Not provided
Not provided
This study will examine how well the Advanix Pancreatic stent helps drainage of the pancreas when used per standard-of-practice in many different situations.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Paul Tarnasky, MD | The Methodist Hospital Research Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Temple University School of Medicine | Philadelphia | Pennsylvania | 19140 | United States | ||
| Medical University of South Carolina |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluation of technical success defined as the ability to place the stent in a satisfactory position in the main pancreatic duct as determined by fluoroscopy. |
| Stent Placement |
| Ease of use | Evaluation of ease of use documenting overall ease of placement, pushability of stent and ability to visualize the stent fluoroscopically. | Stent Placement |
| Removability | Evaluation of removability defined as ability to remove the Advanix stent endoscopically without serious stent removal related adverse events. | Stent Removal |
| Stent Migration | Documentation of stent migration rates overall, by Group, and by stent type | Through end of study |
| Reintervention | Evaluation of the occurrence of reintervention defined as any type of endoscopic, percutaneous, or surgical procedure to aid drainage of the pancreas after initial stent placement through end of follow-up. | Through end of study |
| Stent type preference | Documenting stent type preference by subject presentation and pancreatic plastic stenting indication. | Stent Placement |
| Charleston |
| South Carolina |
| 29425 |
| United States |
| Methodist Dallas Medical Center | Dallas | Texas | 75208 | United States |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | United States |
| Evangelisches Krankenhaus Dusseldorf | Düsseldorf | 40217 | Germany |
| Asian Institute of Gastroenterology | Somājigūda | Hyderabad | 500 082 | India |
| Erasmus Medical Center | Rotterdam | 3015 CE | Netherlands |